Norethindrone

Norethindrone is a lipid of Sterol Lipids (ST) class. Norethindrone is associated with abnormalities such as Endometriosis, site unspecified, Wiskott-Aldrich Syndrome and Estrogenic effect. The involved functions are known as Hemorrhage, Phosphorylation, Apoptosis, DNA Repair and Cell Cycle. Norethindrone often locates in Blood, Back, Body tissue, Nucleolar and Human tissue. The associated genes with Norethindrone are MMP gene, NR3C1 gene and Genes, Reporter. The related lipids are Steroids, 4,17 beta-dihydroxy-4-androstene-3-one, 4-estren-3,17-diol and Estranes.

Cross Reference

Introduction

To understand associated biological information of Norethindrone, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Norethindrone?

Norethindrone is suspected in Endometriosis, site unspecified, Estrogenic effect and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Norethindrone

MeSH term MeSH ID Detail
Pancreatic Neoplasms D010190 77 associated lipids
Arteriosclerosis D001161 86 associated lipids
Body Weight D001835 333 associated lipids
Total 3

PubChem Associated disorders and diseases

What pathways are associated with Norethindrone

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Norethindrone?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Norethindrone?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Norethindrone?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Norethindrone?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Norethindrone?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Norethindrone

Download all related citations
Per page 10 20 50 100 | Total 3869
Authors Title Published Journal PubMed Link
Boon J et al. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. 2003 Maturitas pmid:12963171
Kurtay G et al. A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women. 2006 Maturitas pmid:16325022
Kaiser R Duration of the climacteric syndrome in women treated by hormonal substitution and in controls. 1984 Maturitas pmid:6727694
Campagnoli C et al. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. 1994 Maturitas pmid:7935029
Lundström E et al. Digitized assessment of mammographic breast density--effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. 2011 Maturitas pmid:21958943
Perry W and Wiseman RA Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, haematology and biochemistry. 2002 Maturitas pmid:12065175
Pedersen NG et al. Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits. 2004 Maturitas pmid:15531126
Piccioni P et al. Hormonal replacement therapy after stem cell transplantation. 2004 Maturitas pmid:15531129
Gotfredsen A et al. Effect of natural oestrogen/gestagen therapy on uric acid metabolism in post-menopausal women. 1983 Maturitas pmid:6348486
Samsioe G et al. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. 2007 Maturitas pmid:17317046
Eiken P and Kolthoff N Compliance with long-term oral hormonal replacement therapy. 1995 Maturitas pmid:8538490
Abdalla HI et al. Sex steroid replacement in post-menopausal women: effects on thyroid hormone status. 1987 Maturitas pmid:3037279
Simsek T et al. Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. 2002 Maturitas pmid:12161049
Volpe A et al. Benefits and risks of different hormonal replacement therapies in post-menopausal women. 1986 Maturitas pmid:3033444
Bjarnason K et al. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. 1999 Maturitas pmid:10515673
Fink BJ Endometrial changes after long-term use of continuous oestrogen and cyclic progestogen. 1984 Maturitas pmid:6738374
Bruhat M et al. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. 2001 Maturitas pmid:11731187
Sporrong T et al. A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy. 1989 Maturitas pmid:2593864
Polisseni AF et al. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study. 2013 Maturitas pmid:23201326
Christiansen C et al. Low-risk lipoprotein pattern in post-menopausal women on sequential oestrogen/progestogen treatment. 1984 Maturitas pmid:6727693
Riis BJ et al. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. 1988 Maturitas pmid:3041248
Nahas-Neto J et al. Evaluation of mammographic density and (99m)Tc-sestamibi scintimammographic uptake in postmenopausal women on hormone replacement therapy. 2006 Maturitas pmid:15941630
Grasso A et al. Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. 1982 Maturitas pmid:6285153
Dahmoun M et al. Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. 2004 Maturitas pmid:15474755
Modena MG et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. 2005 Maturitas pmid:15963666
Magos AL et al. Endometrial and menstrual response to subcutaneous oestradiol and testosterone implants and continuous oral progestogen therapy in post-menopausal women. 1985 Maturitas pmid:4079826
Zhou J et al. Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. 2013 Maturitas pmid:23856385
Frenkel Y et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. 1994 Maturitas pmid:7877518
Riis BJ and Christiansen C Post-menopausal bone loss: effects of oestrogens and progestogens. A review. 1986 Maturitas pmid:3553863
Lübbert H and Nauert C Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. 1997 Maturitas pmid:9522319
Gambacciani M et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. 2003 Maturitas pmid:12590012
Glusa E et al. Mechanisms of relaxation of rat aorta in response to progesterone and synthetic progestins. 1997 Maturitas pmid:9522326
Tuppurainen M et al. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up. 2010 Maturitas pmid:20547017
Peverill RE et al. Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. 2006 Maturitas pmid:16368469
Popp AW et al. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. 2006 Maturitas pmid:16368472
Ylöstalo P et al. Serum bile acids and lipids during treatment of climacteric symptoms with natural oestrogen--progestin combinations. 1981 Maturitas pmid:7253932
Biglia N et al. Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens. 2003 Maturitas pmid:12927315
Raudaskoski TH et al. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. 1995 Maturitas pmid:7666816
Lindgren R et al. Transdermal hormonal replacement therapy with transdermal progestin every second month. 1995 Maturitas pmid:7666813
Gambacciani M et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. 2008 Maturitas pmid:18063490
Dören M and Schneider HP Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. 1996 Maturitas pmid:8905600
Taner MZ et al. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study. 2006 Maturitas pmid:15978753
Jensen J et al. Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women. 1989 Maturitas pmid:2547137
Marslew U et al. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. 1994 Maturitas pmid:7799829
Need AG et al. Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. 1986 Maturitas pmid:3574140
Campagnoli C et al. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. 2002 Maturitas pmid:12034517
Obel EB et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. 1993 Maturitas pmid:8429800
Hellberg D and Nilsson S Comparison of a triphasic oestradiol/norethisterone acetate preparation with and without an oestriol component in the treatment of climacteric complaints. 1984 Maturitas pmid:6429481
Keller PJ et al. A transdermal regimen for continuous combined hormone replacement therapy in the menopause. 1992 Maturitas pmid:1465033
Fotherby K Pharmacokinetics of progestational compounds. 1986 Maturitas pmid:2943973